查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1533665

人類類器官的全球市場

Human Organoids
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 383 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

到 2030 年，全球人類類器官市場預計將達到 46 億美元

2023 年全球人類類器官市場估計為 17 億美元，預計到 2030 年將達到 46 億美元，在 2023-2030 年分析期間複合年成長率為 15.5%。腎臟類器官是本報告分析的細分市場之一，預計複合年成長率為 16.3%，到分析期結束時將達到 16 億美元。分析期間，肝臟類器官領域的複合年成長率估計為 16.7%。

美國市場預計為 4.539 億美元，而中國預計複合年成長率為 20.7%

到 2023 年，美國人類類器官市場預計將達到 4.539 億美元。中國作為全球第二大經濟體，預計2030年市場規模將達10億美元，2023-2030年分析期間複合年成長率為20.7%。其他值得注意的區域市場包括日本和加拿大，在分析期間預計複合年成長率分別為 11.7% 和 13.7%。在歐洲，德國的複合年成長率預計約為 12.4%。

全球人類類器官市場－主要促進因素和趨勢總結

人類類器官是人體器官的3D、微型化和簡化版本，由幹細胞在試管內生長。這些類器官模仿真實器官的結構和功能，為研究人類生物學和疾病提供更精確的模型。它們可以由各種類型的幹細胞發育而來，包括誘導性多功能幹細胞（iPSC）和成體幹細胞，並且可以自組織成器官特異性細胞類型。人類類器官已為許多器官（包括大腦、肝臟、腎臟和腸道）創建，為生物醫學研究、藥物開發和個人化醫療提供了突破性工具。

人類類器官的應用大大增進了我們對人類發育和疾病機制的理解。研究人員使用類器官來研究器官形成、遺傳疾病模型，並在與人體非常相似的受控環境中研究各種治療的效果。這些成果在確定新藥物標靶和闡明癌症、神經退化性疾病和感染疾病等複雜疾病的發病機制方面取得了突破。此外，人類類器官已成為再生醫學的寶貴工具，並用於探索器官修復和替代的潛在治療方法。幹細胞研究、生物工程和 3D 培養技術的創新正在加速類器官技術的發展，從而產生更複雜且更強大的模型。

人類類器官市場的成長受到多種因素的推動。首先，慢性病的增加和對有效治療的需求增加了對能夠準確模仿人類生理學的先進研究模型的需求。其次，幹細胞技術和 3D 生物列印的進步正在促進更複雜和更豐富的類器官的開發。此外，個人化醫療的推動正在推動類器官的採用。這是因為類器官可以從個別患者的細胞中產生，以提供量身定做的治療。生物技術和藥物研究投資的增加也推動了市場的成長，大量資金投入類器官的研究和開發。此外，學術機構和行業相關人員之間的監管支持和合作正在加速基於類器官的應用的商業化。最後，與動物模型相比，傾向於使用類器官的倫理考量也有助於市場擴張，因為它們可能為臨床前測試提供更人道、更準確的替代方案。

受訪企業範例（38家知名企業）

  • BioIVT, LLC
  • Cellaion SA
  • CN Bio Innovations Ltd
  • Corning Incorporated
  • CYPRIO
  • InSphero AG
  • KaLy-Cell
  • Kirkstall Ltd.
  • MIMETAS
  • Organovo Holdings, Inc.
  • PRIMACYT Cell Culture Technology GmbH
  • Stemcell Technologies Canada, Inc.
  • Thermo Fisher Scientific Inc.
  • Visikol, Inc.
  • WEPREDIC Group
  • ZenBio, Inc;

目錄

第1章調查方法

第 2 章執行摘要

  • 市場概況
  • 主要企業
  • 市場趨勢和促進因素
  • 全球市場展望

第3章市場分析

  • 美國
  • 加拿大
  • 日本
  • 中國
  • 歐洲
  • 法國
  • 德國
  • 義大利
  • 英國
  • 西班牙
  • 俄羅斯
  • 其他歐洲國家
  • 亞太地區
  • 澳洲
  • 印度
  • 韓國
  • 其他亞太地區
  • 拉丁美洲
  • 阿根廷
  • 巴西
  • 墨西哥
  • 其他拉丁美洲
  • 中東
  • 伊朗
  • 以色列
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 其他中東地區
  • 非洲

第4章 比賽

簡介目錄
Product Code: MCP26604

Global Human Organoids Market to Reach US$4.6 Billion by 2030

The global market for Human Organoids estimated at US$1.7 Billion in the year 2023, is expected to reach US$4.6 Billion by 2030, growing at a CAGR of 15.5% over the analysis period 2023-2030. Kidney Organoids, one of the segments analyzed in the report, is expected to record a 16.3% CAGR and reach US$1.6 Billion by the end of the analysis period. Growth in the Liver Organoids segment is estimated at 16.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$453.9 Million While China is Forecast to Grow at 20.7% CAGR

The Human Organoids market in the U.S. is estimated at US$453.9 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$1.0 Billion by the year 2030 trailing a CAGR of 20.7% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 11.7% and 13.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 12.4% CAGR.

Global Human Organoids Market - Key Drivers and Trends Summarized

Human organoids are three-dimensional, miniaturized, and simplified versions of human organs that are grown in vitro from stem cells. These organoids mimic the structure and function of real organs, providing a more accurate model for studying human biology and disease. They can be developed from various types of stem cells, including induced pluripotent stem cells (iPSCs) and adult stem cells, and are capable of self-organizing into organ-specific cell types. Human organoids have been created for numerous organs, including the brain, liver, kidneys, and intestines, offering a revolutionary tool for biomedical research, drug development, and personalized medicine.

The application of human organoids has significantly advanced our understanding of human development and disease mechanisms. Researchers utilize organoids to study organogenesis, model genetic disorders, and investigate the effects of various treatments in a controlled environment that closely resembles the human body. This has led to breakthroughs in identifying new drug targets and understanding the pathology of complex diseases, such as cancer, neurodegenerative disorders, and infectious diseases. Moreover, human organoids have emerged as valuable tools in regenerative medicine, where they are used to explore potential therapies for organ repair and replacement. The development of organoid technology has been accelerated by innovations in stem cell research, bioengineering, and 3D culture techniques, resulting in more sophisticated and functional models.

The growth in the human organoids market is driven by several factors. Firstly, the increasing prevalence of chronic diseases and the need for effective treatments have spurred demand for advanced research models that can accurately mimic human physiology. Secondly, advancements in stem cell technology and 3D bioprinting have facilitated the development of more complex and functional organoids. Additionally, the push for personalized medicine has boosted the adoption of organoids, as they can be derived from individual patients' cells to tailor treatments. The rising investment in biotechnology and pharmaceutical research has further propelled market growth, with substantial funding directed towards organoid research and development. Furthermore, regulatory support and collaboration between academic institutions and industry players have accelerated the commercialization of organoid-based applications. Lastly, ethical considerations favoring the use of organoids over animal models have also contributed to the market's expansion, as they offer a more humane and potentially more accurate alternative for preclinical testing.

Select Competitors (Total 38 Featured) -

  • BioIVT, LLC
  • Cellaion SA
  • CN Bio Innovations Ltd
  • Corning Incorporated
  • CYPRIO
  • InSphero AG
  • KaLy-Cell
  • Kirkstall Ltd.
  • MIMETAS
  • Organovo Holdings, Inc.
  • PRIMACYT Cell Culture Technology GmbH
  • Stemcell Technologies Canada, Inc.
  • Thermo Fisher Scientific Inc.
  • Visikol, Inc.
  • WEPREDIC Group
  • ZenBio, Inc;

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Global Economic Update
    • Human Organoids - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Demand for Personalized Medicine Drives Market Growth for Human Organoids
    • Advancements in Stem Cell Research Enhance Development and Applications of Organoids
    • Increasing Use of Organoids in Drug Discovery and Development Boosts Market
    • Growing Adoption of Organoids in Disease Modeling Expands Research Opportunities
    • Expansion of 3D Bioprinting Technologies Enhances Organoid Production
    • Growing Interest in Organoids for Toxicology Testing and Safety Assessment
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Human Organoids Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Human Organoids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Human Organoids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Human Organoids by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Kidney by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Kidney by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Kidney by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Liver by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Liver by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Liver by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Lungs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Lungs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Lungs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Pancreas by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Pancreas by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Pancreas by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Other Organ Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Other Organ Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Other Organ Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Regenerative Medicine Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Regenerative Medicine Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 22: World 16-Year Perspective for Regenerative Medicine Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Developmental Biology Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Developmental Biology Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 25: World 16-Year Perspective for Developmental Biology Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Drug Toxicity & Efficacy Testing Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Drug Toxicity & Efficacy Testing Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 28: World 16-Year Perspective for Drug Toxicity & Efficacy Testing Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Disease Pathology Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Disease Pathology Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 31: World 16-Year Perspective for Disease Pathology Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Personalized Medicine Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Personalized Medicine Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 34: World 16-Year Perspective for Personalized Medicine Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Pharma & Biotech Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Pharma & Biotech Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 37: World 16-Year Perspective for Pharma & Biotech Companies End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 38: World Recent Past, Current & Future Analysis for Clinical Research Organizations End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 39: World Historic Review for Clinical Research Organizations End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 40: World 16-Year Perspective for Clinical Research Organizations End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 41: World Recent Past, Current & Future Analysis for Academic Institutes End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 42: World Historic Review for Academic Institutes End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 43: World 16-Year Perspective for Academic Institutes End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Human Organoids Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 44: USA Recent Past, Current & Future Analysis for Human Organoids by Organ Type - Kidney, Liver, Lungs, Pancreas and Other Organ Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 45: USA Historic Review for Human Organoids by Organ Type - Kidney, Liver, Lungs, Pancreas and Other Organ Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 46: USA 16-Year Perspective for Human Organoids by Organ Type - Percentage Breakdown of Value Sales for Kidney, Liver, Lungs, Pancreas and Other Organ Types for the Years 2014, 2024 & 2030
    • TABLE 47: USA Recent Past, Current & Future Analysis for Human Organoids by Application - Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 48: USA Historic Review for Human Organoids by Application - Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 49: USA 16-Year Perspective for Human Organoids by Application - Percentage Breakdown of Value Sales for Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application for the Years 2014, 2024 & 2030
    • TABLE 50: USA Recent Past, Current & Future Analysis for Human Organoids by End-Use - Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 51: USA Historic Review for Human Organoids by End-Use - Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 52: USA 16-Year Perspective for Human Organoids by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 53: Canada Recent Past, Current & Future Analysis for Human Organoids by Organ Type - Kidney, Liver, Lungs, Pancreas and Other Organ Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Canada Historic Review for Human Organoids by Organ Type - Kidney, Liver, Lungs, Pancreas and Other Organ Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 55: Canada 16-Year Perspective for Human Organoids by Organ Type - Percentage Breakdown of Value Sales for Kidney, Liver, Lungs, Pancreas and Other Organ Types for the Years 2014, 2024 & 2030
    • TABLE 56: Canada Recent Past, Current & Future Analysis for Human Organoids by Application - Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Canada Historic Review for Human Organoids by Application - Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 58: Canada 16-Year Perspective for Human Organoids by Application - Percentage Breakdown of Value Sales for Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application for the Years 2014, 2024 & 2030
    • TABLE 59: Canada Recent Past, Current & Future Analysis for Human Organoids by End-Use - Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 60: Canada Historic Review for Human Organoids by End-Use - Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 61: Canada 16-Year Perspective for Human Organoids by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use for the Years 2014, 2024 & 2030
  • JAPAN
    • Human Organoids Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 62: Japan Recent Past, Current & Future Analysis for Human Organoids by Organ Type - Kidney, Liver, Lungs, Pancreas and Other Organ Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Japan Historic Review for Human Organoids by Organ Type - Kidney, Liver, Lungs, Pancreas and Other Organ Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 64: Japan 16-Year Perspective for Human Organoids by Organ Type - Percentage Breakdown of Value Sales for Kidney, Liver, Lungs, Pancreas and Other Organ Types for the Years 2014, 2024 & 2030
    • TABLE 65: Japan Recent Past, Current & Future Analysis for Human Organoids by Application - Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Japan Historic Review for Human Organoids by Application - Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 67: Japan 16-Year Perspective for Human Organoids by Application - Percentage Breakdown of Value Sales for Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application for the Years 2014, 2024 & 2030
    • TABLE 68: Japan Recent Past, Current & Future Analysis for Human Organoids by End-Use - Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Japan Historic Review for Human Organoids by End-Use - Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 70: Japan 16-Year Perspective for Human Organoids by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use for the Years 2014, 2024 & 2030
  • CHINA
    • Human Organoids Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 71: China Recent Past, Current & Future Analysis for Human Organoids by Organ Type - Kidney, Liver, Lungs, Pancreas and Other Organ Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 72: China Historic Review for Human Organoids by Organ Type - Kidney, Liver, Lungs, Pancreas and Other Organ Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 73: China 16-Year Perspective for Human Organoids by Organ Type - Percentage Breakdown of Value Sales for Kidney, Liver, Lungs, Pancreas and Other Organ Types for the Years 2014, 2024 & 2030
    • TABLE 74: China Recent Past, Current & Future Analysis for Human Organoids by Application - Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 75: China Historic Review for Human Organoids by Application - Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 76: China 16-Year Perspective for Human Organoids by Application - Percentage Breakdown of Value Sales for Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application for the Years 2014, 2024 & 2030
    • TABLE 77: China Recent Past, Current & Future Analysis for Human Organoids by End-Use - Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 78: China Historic Review for Human Organoids by End-Use - Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 79: China 16-Year Perspective for Human Organoids by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use for the Years 2014, 2024 & 2030
  • EUROPE
    • Human Organoids Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 80: Europe Recent Past, Current & Future Analysis for Human Organoids by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 81: Europe Historic Review for Human Organoids by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 82: Europe 16-Year Perspective for Human Organoids by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 83: Europe Recent Past, Current & Future Analysis for Human Organoids by Organ Type - Kidney, Liver, Lungs, Pancreas and Other Organ Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Europe Historic Review for Human Organoids by Organ Type - Kidney, Liver, Lungs, Pancreas and Other Organ Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 85: Europe 16-Year Perspective for Human Organoids by Organ Type - Percentage Breakdown of Value Sales for Kidney, Liver, Lungs, Pancreas and Other Organ Types for the Years 2014, 2024 & 2030
    • TABLE 86: Europe Recent Past, Current & Future Analysis for Human Organoids by Application - Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Europe Historic Review for Human Organoids by Application - Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 88: Europe 16-Year Perspective for Human Organoids by Application - Percentage Breakdown of Value Sales for Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application for the Years 2014, 2024 & 2030
    • TABLE 89: Europe Recent Past, Current & Future Analysis for Human Organoids by End-Use - Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Europe Historic Review for Human Organoids by End-Use - Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 91: Europe 16-Year Perspective for Human Organoids by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use for the Years 2014, 2024 & 2030
  • FRANCE
    • Human Organoids Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 92: France Recent Past, Current & Future Analysis for Human Organoids by Organ Type - Kidney, Liver, Lungs, Pancreas and Other Organ Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 93: France Historic Review for Human Organoids by Organ Type - Kidney, Liver, Lungs, Pancreas and Other Organ Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 94: France 16-Year Perspective for Human Organoids by Organ Type - Percentage Breakdown of Value Sales for Kidney, Liver, Lungs, Pancreas and Other Organ Types for the Years 2014, 2024 & 2030
    • TABLE 95: France Recent Past, Current & Future Analysis for Human Organoids by Application - Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 96: France Historic Review for Human Organoids by Application - Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 97: France 16-Year Perspective for Human Organoids by Application - Percentage Breakdown of Value Sales for Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application for the Years 2014, 2024 & 2030
    • TABLE 98: France Recent Past, Current & Future Analysis for Human Organoids by End-Use - Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 99: France Historic Review for Human Organoids by End-Use - Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 100: France 16-Year Perspective for Human Organoids by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use for the Years 2014, 2024 & 2030
  • GERMANY
    • Human Organoids Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 101: Germany Recent Past, Current & Future Analysis for Human Organoids by Organ Type - Kidney, Liver, Lungs, Pancreas and Other Organ Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Germany Historic Review for Human Organoids by Organ Type - Kidney, Liver, Lungs, Pancreas and Other Organ Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 103: Germany 16-Year Perspective for Human Organoids by Organ Type - Percentage Breakdown of Value Sales for Kidney, Liver, Lungs, Pancreas and Other Organ Types for the Years 2014, 2024 & 2030
    • TABLE 104: Germany Recent Past, Current & Future Analysis for Human Organoids by Application - Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Germany Historic Review for Human Organoids by Application - Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 106: Germany 16-Year Perspective for Human Organoids by Application - Percentage Breakdown of Value Sales for Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application for the Years 2014, 2024 & 2030
    • TABLE 107: Germany Recent Past, Current & Future Analysis for Human Organoids by End-Use - Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Germany Historic Review for Human Organoids by End-Use - Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 109: Germany 16-Year Perspective for Human Organoids by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 110: Italy Recent Past, Current & Future Analysis for Human Organoids by Organ Type - Kidney, Liver, Lungs, Pancreas and Other Organ Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 111: Italy Historic Review for Human Organoids by Organ Type - Kidney, Liver, Lungs, Pancreas and Other Organ Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 112: Italy 16-Year Perspective for Human Organoids by Organ Type - Percentage Breakdown of Value Sales for Kidney, Liver, Lungs, Pancreas and Other Organ Types for the Years 2014, 2024 & 2030
    • TABLE 113: Italy Recent Past, Current & Future Analysis for Human Organoids by Application - Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 114: Italy Historic Review for Human Organoids by Application - Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 115: Italy 16-Year Perspective for Human Organoids by Application - Percentage Breakdown of Value Sales for Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application for the Years 2014, 2024 & 2030
    • TABLE 116: Italy Recent Past, Current & Future Analysis for Human Organoids by End-Use - Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 117: Italy Historic Review for Human Organoids by End-Use - Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 118: Italy 16-Year Perspective for Human Organoids by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Human Organoids Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 119: UK Recent Past, Current & Future Analysis for Human Organoids by Organ Type - Kidney, Liver, Lungs, Pancreas and Other Organ Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 120: UK Historic Review for Human Organoids by Organ Type - Kidney, Liver, Lungs, Pancreas and Other Organ Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 121: UK 16-Year Perspective for Human Organoids by Organ Type - Percentage Breakdown of Value Sales for Kidney, Liver, Lungs, Pancreas and Other Organ Types for the Years 2014, 2024 & 2030
    • TABLE 122: UK Recent Past, Current & Future Analysis for Human Organoids by Application - Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 123: UK Historic Review for Human Organoids by Application - Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 124: UK 16-Year Perspective for Human Organoids by Application - Percentage Breakdown of Value Sales for Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application for the Years 2014, 2024 & 2030
    • TABLE 125: UK Recent Past, Current & Future Analysis for Human Organoids by End-Use - Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 126: UK Historic Review for Human Organoids by End-Use - Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 127: UK 16-Year Perspective for Human Organoids by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 128: Spain Recent Past, Current & Future Analysis for Human Organoids by Organ Type - Kidney, Liver, Lungs, Pancreas and Other Organ Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 129: Spain Historic Review for Human Organoids by Organ Type - Kidney, Liver, Lungs, Pancreas and Other Organ Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 130: Spain 16-Year Perspective for Human Organoids by Organ Type - Percentage Breakdown of Value Sales for Kidney, Liver, Lungs, Pancreas and Other Organ Types for the Years 2014, 2024 & 2030
    • TABLE 131: Spain Recent Past, Current & Future Analysis for Human Organoids by Application - Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 132: Spain Historic Review for Human Organoids by Application - Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 133: Spain 16-Year Perspective for Human Organoids by Application - Percentage Breakdown of Value Sales for Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application for the Years 2014, 2024 & 2030
    • TABLE 134: Spain Recent Past, Current & Future Analysis for Human Organoids by End-Use - Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 135: Spain Historic Review for Human Organoids by End-Use - Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 136: Spain 16-Year Perspective for Human Organoids by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 137: Russia Recent Past, Current & Future Analysis for Human Organoids by Organ Type - Kidney, Liver, Lungs, Pancreas and Other Organ Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 138: Russia Historic Review for Human Organoids by Organ Type - Kidney, Liver, Lungs, Pancreas and Other Organ Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 139: Russia 16-Year Perspective for Human Organoids by Organ Type - Percentage Breakdown of Value Sales for Kidney, Liver, Lungs, Pancreas and Other Organ Types for the Years 2014, 2024 & 2030
    • TABLE 140: Russia Recent Past, Current & Future Analysis for Human Organoids by Application - Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 141: Russia Historic Review for Human Organoids by Application - Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 142: Russia 16-Year Perspective for Human Organoids by Application - Percentage Breakdown of Value Sales for Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application for the Years 2014, 2024 & 2030
    • TABLE 143: Russia Recent Past, Current & Future Analysis for Human Organoids by End-Use - Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 144: Russia Historic Review for Human Organoids by End-Use - Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 145: Russia 16-Year Perspective for Human Organoids by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Human Organoids by Organ Type - Kidney, Liver, Lungs, Pancreas and Other Organ Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 147: Rest of Europe Historic Review for Human Organoids by Organ Type - Kidney, Liver, Lungs, Pancreas and Other Organ Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 148: Rest of Europe 16-Year Perspective for Human Organoids by Organ Type - Percentage Breakdown of Value Sales for Kidney, Liver, Lungs, Pancreas and Other Organ Types for the Years 2014, 2024 & 2030
    • TABLE 149: Rest of Europe Recent Past, Current & Future Analysis for Human Organoids by Application - Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 150: Rest of Europe Historic Review for Human Organoids by Application - Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 151: Rest of Europe 16-Year Perspective for Human Organoids by Application - Percentage Breakdown of Value Sales for Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application for the Years 2014, 2024 & 2030
    • TABLE 152: Rest of Europe Recent Past, Current & Future Analysis for Human Organoids by End-Use - Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 153: Rest of Europe Historic Review for Human Organoids by End-Use - Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 154: Rest of Europe 16-Year Perspective for Human Organoids by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Human Organoids Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Human Organoids by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 156: Asia-Pacific Historic Review for Human Organoids by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 157: Asia-Pacific 16-Year Perspective for Human Organoids by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Human Organoids by Organ Type - Kidney, Liver, Lungs, Pancreas and Other Organ Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 159: Asia-Pacific Historic Review for Human Organoids by Organ Type - Kidney, Liver, Lungs, Pancreas and Other Organ Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 160: Asia-Pacific 16-Year Perspective for Human Organoids by Organ Type - Percentage Breakdown of Value Sales for Kidney, Liver, Lungs, Pancreas and Other Organ Types for the Years 2014, 2024 & 2030
    • TABLE 161: Asia-Pacific Recent Past, Current & Future Analysis for Human Organoids by Application - Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 162: Asia-Pacific Historic Review for Human Organoids by Application - Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 163: Asia-Pacific 16-Year Perspective for Human Organoids by Application - Percentage Breakdown of Value Sales for Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application for the Years 2014, 2024 & 2030
    • TABLE 164: Asia-Pacific Recent Past, Current & Future Analysis for Human Organoids by End-Use - Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 165: Asia-Pacific Historic Review for Human Organoids by End-Use - Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 166: Asia-Pacific 16-Year Perspective for Human Organoids by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Human Organoids Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 167: Australia Recent Past, Current & Future Analysis for Human Organoids by Organ Type - Kidney, Liver, Lungs, Pancreas and Other Organ Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 168: Australia Historic Review for Human Organoids by Organ Type - Kidney, Liver, Lungs, Pancreas and Other Organ Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 169: Australia 16-Year Perspective for Human Organoids by Organ Type - Percentage Breakdown of Value Sales for Kidney, Liver, Lungs, Pancreas and Other Organ Types for the Years 2014, 2024 & 2030
    • TABLE 170: Australia Recent Past, Current & Future Analysis for Human Organoids by Application - Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 171: Australia Historic Review for Human Organoids by Application - Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 172: Australia 16-Year Perspective for Human Organoids by Application - Percentage Breakdown of Value Sales for Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application for the Years 2014, 2024 & 2030
    • TABLE 173: Australia Recent Past, Current & Future Analysis for Human Organoids by End-Use - Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 174: Australia Historic Review for Human Organoids by End-Use - Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 175: Australia 16-Year Perspective for Human Organoids by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use for the Years 2014, 2024 & 2030
  • INDIA
    • Human Organoids Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 176: India Recent Past, Current & Future Analysis for Human Organoids by Organ Type - Kidney, Liver, Lungs, Pancreas and Other Organ Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 177: India Historic Review for Human Organoids by Organ Type - Kidney, Liver, Lungs, Pancreas and Other Organ Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 178: India 16-Year Perspective for Human Organoids by Organ Type - Percentage Breakdown of Value Sales for Kidney, Liver, Lungs, Pancreas and Other Organ Types for the Years 2014, 2024 & 2030
    • TABLE 179: India Recent Past, Current & Future Analysis for Human Organoids by Application - Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 180: India Historic Review for Human Organoids by Application - Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 181: India 16-Year Perspective for Human Organoids by Application - Percentage Breakdown of Value Sales for Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application for the Years 2014, 2024 & 2030
    • TABLE 182: India Recent Past, Current & Future Analysis for Human Organoids by End-Use - Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 183: India Historic Review for Human Organoids by End-Use - Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 184: India 16-Year Perspective for Human Organoids by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 185: South Korea Recent Past, Current & Future Analysis for Human Organoids by Organ Type - Kidney, Liver, Lungs, Pancreas and Other Organ Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 186: South Korea Historic Review for Human Organoids by Organ Type - Kidney, Liver, Lungs, Pancreas and Other Organ Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 187: South Korea 16-Year Perspective for Human Organoids by Organ Type - Percentage Breakdown of Value Sales for Kidney, Liver, Lungs, Pancreas and Other Organ Types for the Years 2014, 2024 & 2030
    • TABLE 188: South Korea Recent Past, Current & Future Analysis for Human Organoids by Application - Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 189: South Korea Historic Review for Human Organoids by Application - Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 190: South Korea 16-Year Perspective for Human Organoids by Application - Percentage Breakdown of Value Sales for Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application for the Years 2014, 2024 & 2030
    • TABLE 191: South Korea Recent Past, Current & Future Analysis for Human Organoids by End-Use - Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 192: South Korea Historic Review for Human Organoids by End-Use - Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 193: South Korea 16-Year Perspective for Human Organoids by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Human Organoids by Organ Type - Kidney, Liver, Lungs, Pancreas and Other Organ Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 195: Rest of Asia-Pacific Historic Review for Human Organoids by Organ Type - Kidney, Liver, Lungs, Pancreas and Other Organ Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 196: Rest of Asia-Pacific 16-Year Perspective for Human Organoids by Organ Type - Percentage Breakdown of Value Sales for Kidney, Liver, Lungs, Pancreas and Other Organ Types for the Years 2014, 2024 & 2030
    • TABLE 197: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Human Organoids by Application - Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 198: Rest of Asia-Pacific Historic Review for Human Organoids by Application - Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 199: Rest of Asia-Pacific 16-Year Perspective for Human Organoids by Application - Percentage Breakdown of Value Sales for Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application for the Years 2014, 2024 & 2030
    • TABLE 200: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Human Organoids by End-Use - Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 201: Rest of Asia-Pacific Historic Review for Human Organoids by End-Use - Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 202: Rest of Asia-Pacific 16-Year Perspective for Human Organoids by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Human Organoids Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 203: Latin America Recent Past, Current & Future Analysis for Human Organoids by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 204: Latin America Historic Review for Human Organoids by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 205: Latin America 16-Year Perspective for Human Organoids by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 206: Latin America Recent Past, Current & Future Analysis for Human Organoids by Organ Type - Kidney, Liver, Lungs, Pancreas and Other Organ Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 207: Latin America Historic Review for Human Organoids by Organ Type - Kidney, Liver, Lungs, Pancreas and Other Organ Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 208: Latin America 16-Year Perspective for Human Organoids by Organ Type - Percentage Breakdown of Value Sales for Kidney, Liver, Lungs, Pancreas and Other Organ Types for the Years 2014, 2024 & 2030
    • TABLE 209: Latin America Recent Past, Current & Future Analysis for Human Organoids by Application - Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 210: Latin America Historic Review for Human Organoids by Application - Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 211: Latin America 16-Year Perspective for Human Organoids by Application - Percentage Breakdown of Value Sales for Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application for the Years 2014, 2024 & 2030
    • TABLE 212: Latin America Recent Past, Current & Future Analysis for Human Organoids by End-Use - Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 213: Latin America Historic Review for Human Organoids by End-Use - Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 214: Latin America 16-Year Perspective for Human Organoids by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 215: Argentina Recent Past, Current & Future Analysis for Human Organoids by Organ Type - Kidney, Liver, Lungs, Pancreas and Other Organ Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 216: Argentina Historic Review for Human Organoids by Organ Type - Kidney, Liver, Lungs, Pancreas and Other Organ Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 217: Argentina 16-Year Perspective for Human Organoids by Organ Type - Percentage Breakdown of Value Sales for Kidney, Liver, Lungs, Pancreas and Other Organ Types for the Years 2014, 2024 & 2030
    • TABLE 218: Argentina Recent Past, Current & Future Analysis for Human Organoids by Application - Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 219: Argentina Historic Review for Human Organoids by Application - Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 220: Argentina 16-Year Perspective for Human Organoids by Application - Percentage Breakdown of Value Sales for Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application for the Years 2014, 2024 & 2030
    • TABLE 221: Argentina Recent Past, Current & Future Analysis for Human Organoids by End-Use - Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 222: Argentina Historic Review for Human Organoids by End-Use - Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 223: Argentina 16-Year Perspective for Human Organoids by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 224: Brazil Recent Past, Current & Future Analysis for Human Organoids by Organ Type - Kidney, Liver, Lungs, Pancreas and Other Organ Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 225: Brazil Historic Review for Human Organoids by Organ Type - Kidney, Liver, Lungs, Pancreas and Other Organ Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 226: Brazil 16-Year Perspective for Human Organoids by Organ Type - Percentage Breakdown of Value Sales for Kidney, Liver, Lungs, Pancreas and Other Organ Types for the Years 2014, 2024 & 2030
    • TABLE 227: Brazil Recent Past, Current & Future Analysis for Human Organoids by Application - Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 228: Brazil Historic Review for Human Organoids by Application - Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 229: Brazil 16-Year Perspective for Human Organoids by Application - Percentage Breakdown of Value Sales for Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application for the Years 2014, 2024 & 2030
    • TABLE 230: Brazil Recent Past, Current & Future Analysis for Human Organoids by End-Use - Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 231: Brazil Historic Review for Human Organoids by End-Use - Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 232: Brazil 16-Year Perspective for Human Organoids by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 233: Mexico Recent Past, Current & Future Analysis for Human Organoids by Organ Type - Kidney, Liver, Lungs, Pancreas and Other Organ Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 234: Mexico Historic Review for Human Organoids by Organ Type - Kidney, Liver, Lungs, Pancreas and Other Organ Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 235: Mexico 16-Year Perspective for Human Organoids by Organ Type - Percentage Breakdown of Value Sales for Kidney, Liver, Lungs, Pancreas and Other Organ Types for the Years 2014, 2024 & 2030
    • TABLE 236: Mexico Recent Past, Current & Future Analysis for Human Organoids by Application - Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 237: Mexico Historic Review for Human Organoids by Application - Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 238: Mexico 16-Year Perspective for Human Organoids by Application - Percentage Breakdown of Value Sales for Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application for the Years 2014, 2024 & 2030
    • TABLE 239: Mexico Recent Past, Current & Future Analysis for Human Organoids by End-Use - Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 240: Mexico Historic Review for Human Organoids by End-Use - Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 241: Mexico 16-Year Perspective for Human Organoids by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Human Organoids by Organ Type - Kidney, Liver, Lungs, Pancreas and Other Organ Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 243: Rest of Latin America Historic Review for Human Organoids by Organ Type - Kidney, Liver, Lungs, Pancreas and Other Organ Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 244: Rest of Latin America 16-Year Perspective for Human Organoids by Organ Type - Percentage Breakdown of Value Sales for Kidney, Liver, Lungs, Pancreas and Other Organ Types for the Years 2014, 2024 & 2030
    • TABLE 245: Rest of Latin America Recent Past, Current & Future Analysis for Human Organoids by Application - Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 246: Rest of Latin America Historic Review for Human Organoids by Application - Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 247: Rest of Latin America 16-Year Perspective for Human Organoids by Application - Percentage Breakdown of Value Sales for Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application for the Years 2014, 2024 & 2030
    • TABLE 248: Rest of Latin America Recent Past, Current & Future Analysis for Human Organoids by End-Use - Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 249: Rest of Latin America Historic Review for Human Organoids by End-Use - Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 250: Rest of Latin America 16-Year Perspective for Human Organoids by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Human Organoids Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 251: Middle East Recent Past, Current & Future Analysis for Human Organoids by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 252: Middle East Historic Review for Human Organoids by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 253: Middle East 16-Year Perspective for Human Organoids by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 254: Middle East Recent Past, Current & Future Analysis for Human Organoids by Organ Type - Kidney, Liver, Lungs, Pancreas and Other Organ Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 255: Middle East Historic Review for Human Organoids by Organ Type - Kidney, Liver, Lungs, Pancreas and Other Organ Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 256: Middle East 16-Year Perspective for Human Organoids by Organ Type - Percentage Breakdown of Value Sales for Kidney, Liver, Lungs, Pancreas and Other Organ Types for the Years 2014, 2024 & 2030
    • TABLE 257: Middle East Recent Past, Current & Future Analysis for Human Organoids by Application - Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 258: Middle East Historic Review for Human Organoids by Application - Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 259: Middle East 16-Year Perspective for Human Organoids by Application - Percentage Breakdown of Value Sales for Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application for the Years 2014, 2024 & 2030
    • TABLE 260: Middle East Recent Past, Current & Future Analysis for Human Organoids by End-Use - Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 261: Middle East Historic Review for Human Organoids by End-Use - Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 262: Middle East 16-Year Perspective for Human Organoids by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 263: Iran Recent Past, Current & Future Analysis for Human Organoids by Organ Type - Kidney, Liver, Lungs, Pancreas and Other Organ Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 264: Iran Historic Review for Human Organoids by Organ Type - Kidney, Liver, Lungs, Pancreas and Other Organ Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 265: Iran 16-Year Perspective for Human Organoids by Organ Type - Percentage Breakdown of Value Sales for Kidney, Liver, Lungs, Pancreas and Other Organ Types for the Years 2014, 2024 & 2030
    • TABLE 266: Iran Recent Past, Current & Future Analysis for Human Organoids by Application - Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 267: Iran Historic Review for Human Organoids by Application - Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 268: Iran 16-Year Perspective for Human Organoids by Application - Percentage Breakdown of Value Sales for Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application for the Years 2014, 2024 & 2030
    • TABLE 269: Iran Recent Past, Current & Future Analysis for Human Organoids by End-Use - Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 270: Iran Historic Review for Human Organoids by End-Use - Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 271: Iran 16-Year Perspective for Human Organoids by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 272: Israel Recent Past, Current & Future Analysis for Human Organoids by Organ Type - Kidney, Liver, Lungs, Pancreas and Other Organ Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 273: Israel Historic Review for Human Organoids by Organ Type - Kidney, Liver, Lungs, Pancreas and Other Organ Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 274: Israel 16-Year Perspective for Human Organoids by Organ Type - Percentage Breakdown of Value Sales for Kidney, Liver, Lungs, Pancreas and Other Organ Types for the Years 2014, 2024 & 2030
    • TABLE 275: Israel Recent Past, Current & Future Analysis for Human Organoids by Application - Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 276: Israel Historic Review for Human Organoids by Application - Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 277: Israel 16-Year Perspective for Human Organoids by Application - Percentage Breakdown of Value Sales for Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application for the Years 2014, 2024 & 2030
    • TABLE 278: Israel Recent Past, Current & Future Analysis for Human Organoids by End-Use - Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 279: Israel Historic Review for Human Organoids by End-Use - Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 280: Israel 16-Year Perspective for Human Organoids by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Human Organoids by Organ Type - Kidney, Liver, Lungs, Pancreas and Other Organ Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 282: Saudi Arabia Historic Review for Human Organoids by Organ Type - Kidney, Liver, Lungs, Pancreas and Other Organ Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 283: Saudi Arabia 16-Year Perspective for Human Organoids by Organ Type - Percentage Breakdown of Value Sales for Kidney, Liver, Lungs, Pancreas and Other Organ Types for the Years 2014, 2024 & 2030
    • TABLE 284: Saudi Arabia Recent Past, Current & Future Analysis for Human Organoids by Application - Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 285: Saudi Arabia Historic Review for Human Organoids by Application - Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 286: Saudi Arabia 16-Year Perspective for Human Organoids by Application - Percentage Breakdown of Value Sales for Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application for the Years 2014, 2024 & 2030
    • TABLE 287: Saudi Arabia Recent Past, Current & Future Analysis for Human Organoids by End-Use - Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 288: Saudi Arabia Historic Review for Human Organoids by End-Use - Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 289: Saudi Arabia 16-Year Perspective for Human Organoids by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 290: UAE Recent Past, Current & Future Analysis for Human Organoids by Organ Type - Kidney, Liver, Lungs, Pancreas and Other Organ Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 291: UAE Historic Review for Human Organoids by Organ Type - Kidney, Liver, Lungs, Pancreas and Other Organ Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 292: UAE 16-Year Perspective for Human Organoids by Organ Type - Percentage Breakdown of Value Sales for Kidney, Liver, Lungs, Pancreas and Other Organ Types for the Years 2014, 2024 & 2030
    • TABLE 293: UAE Recent Past, Current & Future Analysis for Human Organoids by Application - Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 294: UAE Historic Review for Human Organoids by Application - Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 295: UAE 16-Year Perspective for Human Organoids by Application - Percentage Breakdown of Value Sales for Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application for the Years 2014, 2024 & 2030
    • TABLE 296: UAE Recent Past, Current & Future Analysis for Human Organoids by End-Use - Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 297: UAE Historic Review for Human Organoids by End-Use - Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 298: UAE 16-Year Perspective for Human Organoids by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Human Organoids by Organ Type - Kidney, Liver, Lungs, Pancreas and Other Organ Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 300: Rest of Middle East Historic Review for Human Organoids by Organ Type - Kidney, Liver, Lungs, Pancreas and Other Organ Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 301: Rest of Middle East 16-Year Perspective for Human Organoids by Organ Type - Percentage Breakdown of Value Sales for Kidney, Liver, Lungs, Pancreas and Other Organ Types for the Years 2014, 2024 & 2030
    • TABLE 302: Rest of Middle East Recent Past, Current & Future Analysis for Human Organoids by Application - Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 303: Rest of Middle East Historic Review for Human Organoids by Application - Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 304: Rest of Middle East 16-Year Perspective for Human Organoids by Application - Percentage Breakdown of Value Sales for Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application for the Years 2014, 2024 & 2030
    • TABLE 305: Rest of Middle East Recent Past, Current & Future Analysis for Human Organoids by End-Use - Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 306: Rest of Middle East Historic Review for Human Organoids by End-Use - Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 307: Rest of Middle East 16-Year Perspective for Human Organoids by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use for the Years 2014, 2024 & 2030
  • AFRICA
    • Human Organoids Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 308: Africa Recent Past, Current & Future Analysis for Human Organoids by Organ Type - Kidney, Liver, Lungs, Pancreas and Other Organ Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 309: Africa Historic Review for Human Organoids by Organ Type - Kidney, Liver, Lungs, Pancreas and Other Organ Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 310: Africa 16-Year Perspective for Human Organoids by Organ Type - Percentage Breakdown of Value Sales for Kidney, Liver, Lungs, Pancreas and Other Organ Types for the Years 2014, 2024 & 2030
    • TABLE 311: Africa Recent Past, Current & Future Analysis for Human Organoids by Application - Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 312: Africa Historic Review for Human Organoids by Application - Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 313: Africa 16-Year Perspective for Human Organoids by Application - Percentage Breakdown of Value Sales for Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application for the Years 2014, 2024 & 2030
    • TABLE 314: Africa Recent Past, Current & Future Analysis for Human Organoids by End-Use - Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 315: Africa Historic Review for Human Organoids by End-Use - Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 316: Africa 16-Year Perspective for Human Organoids by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use for the Years 2014, 2024 & 2030

IV. COMPETITION